This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

22 Apr 2011

Johnson & Johnson Announces Earnings for 1Q11

J&J has announced its financial results for the first quarter ended March 2011.

Johnson & Johnson, the world's second largest health care products manufacturer, announced its Q1 financial report this week.


The company's worldwide Pharmaceutical sales were $6.1 billion in the quarter (+8%), with domestic sales down 1% and international sales up 7%.


Remicade sales were up 8% to $1.3 billion. Levaquin/Floxin sales were up 17% to $434 million. Concerta sales were up 10% to $362 million. Prezista sales were up 42% to $266 million. Procrit/Eprex sales were down 24% to $397 million. Topamax sales were down 13% to $129 million. Worldwide Consumer sales were $3.7 billion (-2%), with domestic sales down 14%, impacted by the suspension of manufacturing at the McNe

Related News